A detailed history of Caption Management, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Caption Management, LLC holds 192,000 shares of VRDN stock, worth $3.71 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
192,000
Previous 99,700 92.58%
Holding current value
$3.71 Million
Previous $1.3 Million 236.78%
% of portfolio
0.08%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $223,880 - $333,118
19,300 Added 77.2%
44,300 $576,000
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $427,250 - $595,500
25,000 New
25,000 $437,000
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $473,970 - $623,070
21,000 Added 140.0%
36,000 $856,000
Q1 2023

May 15, 2023

BUY
$25.04 - $37.6 $375,600 - $564,000
15,000 New
15,000 $381,000
Q2 2022

Aug 15, 2022

BUY
$9.55 - $19.0 $169,770 - $337,763
17,777 New
17,777 $206,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $770M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.